01.07.2009 | News and Views
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question
Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2009
Einloggen, um Zugang zu erhalten